Skip to main content
Clinical Trials/NCT00855166
NCT00855166
Completed
Phase 3

A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-Controlled,Phase III Study With a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

AstraZeneca1 site in 1 country182 target enrollmentFebruary 2009

Overview

Phase
Phase 3
Intervention
Sitagliptin
Conditions
Type 2 Diabetes Mellitus
Sponsor
AstraZeneca
Enrollment
182
Locations
1
Primary Endpoint
Adjusted Mean Change in Total Body Weight
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone.

Registry
clinicaltrials.gov
Start Date
February 2009
End Date
December 2011
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Type 2 diabetes
  • Ongoing treatment with metformin on a stable dose of ≥1500 mg/day for at least 12 weeks prior to enrolment
  • Inadequate glycemic control, defined as HbA1c ≥6.5% and ≤8.5%
  • ≥30 years for males
  • ≥55 years for females

Exclusion Criteria

  • Type 1 Diabetes
  • Body weight change \>5% within 3 months prior to enrolment
  • Renal and liver impairment

Arms & Interventions

A

Dapagliflozin 10 mg plus Metformin

Intervention: Sitagliptin

A

Dapagliflozin 10 mg plus Metformin

Intervention: Dapagliflozin

A

Dapagliflozin 10 mg plus Metformin

Intervention: Metformin

B

Placebo plus Metformin

Intervention: Metformin

B

Placebo plus Metformin

Intervention: Sitagliptin

B

Placebo plus Metformin

Intervention: Placebo

Outcomes

Primary Outcomes

Adjusted Mean Change in Total Body Weight

Time Frame: Baseline to Week 24

To evaluate the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin on total body weight after 24 weeks of oral administration of double-blind treatment.

Secondary Outcomes

  • Adjusted Mean Change in Body Fat Mass(Baseline to Week 24)
  • Proportion of Participants With Body Weight Decrease ≥5%(Baseline to Week 24)
  • Adjusted Mean Change in Waist Circumference(Baseline to Week 24)

Study Sites (1)

Loading locations...

Similar Trials